Vesparax

Quick links to important sections

Vesparax

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vesparax

The medication Vesparax (Quetiapine) is a prescription-only drug whose identity and purpose are defined by its active ingredient, a core component in the management of complex mental health conditions.

Property Description
Active ingredient Quetiapine (fumarate/hemifumarate)
Form Tablet, Film-coated tablet, Extended-release (XR) tablet
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic)
General purpose To help stabilize mood, perception, and thought processes
Origin Synthetic compound (Dibenzo[b,f][1,4]thiazepine derivative)

What is Vesparax and its Pharmacological Class?

Vesparax is a single-ingredient product known by its chemical name, quetiapine, a recognized psychotropic agent. It is classified as an atypical antipsychotic, which is the preferred term for second-generation antipsychotics. This classification defines its role as a medication used to modulate chemical activity in the central nervous system. It is clinically recognized for modulating neural pathways involved in severe mood and thought disturbances.

Quetiapine: Synthetic Origin and Available Forms

The active ingredient, quetiapine, is a synthetic compound derived from the dibenzo[b,f][1,4]thiazepine derivative chemical class. It is intended for the oral route of administration and is manufactured as an oral dosage form, specifically a tablet or film-coated tablet. Quetiapine is used to treat psychiatric disorders and its chemical structure is characterized as a dibenzothiazepine derivative. The medication acts by managing the chemical activity of key neurotransmitters in the brain, supporting stability in conditions that affect the adult and adolescent patient group.

General Purpose and Action Principle

The core purpose of this medication is to help restore equilibrium to the brain's activity. It achieves this through multi-receptor antagonism, a mechanism where it acts as a blocking agent for various neurotransmitter receptors, including those for dopamine and serotonin. This sophisticated modulation of different neurotransmitter systems supports the stabilization of severe emotional and cognitive states. By precisely modulating these chemical pathways, the drug supports the maintenance of functional cognitive and emotional stability, which is a key goal in managing conditions like schizophrenia and bipolar disorder.

Regulatory References

  1. NIH: Antipsychotic Medications - StatPearls - NCBI

What side effects are possible with Vesparax?

Possible Side Effects and Safety Information

The safety characteristics of Vesparax (Quetiapine) are organized by regulatory authorities according to observed frequency and affected body system. This profile describes the high-level adverse effects and safety constraints documented in official labeling.

Frequency-Classified Adverse Reactions

Adverse effects are documented in categories based on their rate of occurrence in clinical data:

  • Very Common (affecting 1 in 10 or more): Somnolence (drowsiness), Dizziness, Dry mouth, and Weight gain.
  • Common (affecting 1 in 100 to less than 1 in 10): Constipation, Orthostatic hypotension (low blood pressure on standing), Tachycardia, Headache, Extrapyramidal symptoms (EPS), and elevations in serum triglycerides and cholesterol.

Serious Safety Considerations

Official labeling highlights critical safety risks, including boxed warnings for certain patient groups. These include the documented Increased Mortality in Elderly Patients with Dementia-Related Psychosis and the risk of Suicidal Thoughts and Behaviors in children, adolescents, and young adults. Other serious adverse reactions listed include Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (potentially irreversible involuntary movements), and significant Metabolic Changes such as hyperglycemia.

Contextual Safety Patterns

Safety notes tied to the treatment course are included in regulatory documents. Orthostatic hypotension and related dizziness are generally more likely to occur during the initial dose-titration period. Conversely, the development of conditions like Cataracts or Tardive Dyskinesia are associated with long-term exposure to the medicine. Abrupt cessation of Quetiapine is also associated with documented withdrawal symptoms.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Vesparax (quetiapine) requires immediate medical attention. Contact emergency services or a poison control center right away. The effects of an overdose are characterized by an extreme exaggeration of the drug’s pharmacological actions, as documented in regulatory sources.

Documented Manifestations and Severe Outcomes

Official documentation specifies that overdose may present with signs of significant CNS depression, including somnolence and drowsiness, which can progress to coma. Cardiovascular effects are commonly documented, such as tachycardia (rapid heart rate) and hypotension (low blood pressure). Severe or life-threatening outcomes reported include respiratory depression or failure, prolonged seizures (status epilepticus), and in rare, massive ingestions, death.

Official Management and Monitoring

Management is officially designated as symptomatic and supportive, as no specific antidote is known for quetiapine. Emergency procedures mandated by regulatory authorities include securing and maintaining a patent airway and ensuring adequate ventilation. Continuous ECG monitoring is required due to the risk of cardiovascular events, including QT interval prolongation. Individuals with pre-existing severe cardiovascular disease are noted to be at an increased risk of adverse effects following an overdose.

Therapeutic Uses of Vesparax

What Vesparax Treats: Main Uses and Benefits

The primary role of Vesparax is to provide symptomatic relief and may be part of symptomatic management to help assist with maintaining functional stability in several severe mental health conditions. Its use is recognized across therapeutic domains where patient distress and functional strain are significant.


Stabilizing Thought and Perception in Psychosis

This medication is applied in conditions marked by profound thought disturbances, such as Schizophrenia, affecting adults and adolescents aged 13 and older. It helps address severe symptoms like hallucinations and delusions, which create noticeable interference with a patient's grasp of reality. Using this medication can contribute to easing the overall symptom load, offering support that helps patients cope more steadily with these difficult manifestations.

Moderating Mood and Depression

Vesparax is commonly used across conditions characterized by episodic mood fluctuations, relevant in the symptomatic management of Bipolar I and II Disorders. It is applied in clinical settings that involve acute or unstable symptom patterns, assisting with symptom stabilization during acute manic, mixed, or depressive episodes, and may be part of long-term maintenance treatment that supports patients against the recurrence of episodes. It is also relevant as an adjunctive therapy for Major Depressive Disorder (MDD) in adults when patients experience symptoms that continue despite initial treatment.

Quick Fact: Relief for Manic Symptoms Vesparax is used for managing challenging symptoms like frenzied mood, hyperactivity, and excessive talkativeness, and may assist with maintaining functional stability.

“The approach is relevant in contexts involving heightened systemic burden, supporting patients during difficult episodes by easing distress.”

In summary, Vesparax is commonly used to help manage Schizophrenia, acute manic episodes associated with Bipolar Disorder, bipolar depression, and as adjunctive therapy for Major Depressive Disorder.

Eligibility and Restrictions for Use

Who Can and Cannot Use Vesparax

The eligibility profile for Vesparax (Quetiapine) is defined by official regulatory criteria that specify permissible and prohibited patient groups.

Eligibility Category Status Defined by Regulatory Agencies
Absolute Contraindications Must Not Use: Individuals with known hypersensitivity to the drug. Not Approved/Contraindicated: Elderly patients with dementia-related psychosis (due to increased mortality risk).
Approved Age Groups Adults for all labeled indications. Adolescents mathbf13–mathbf17 for Schizophrenia. Children/Adolescents mathbf10–mathbf17 for Bipolar Mania.

Eligibility Restrictions and Conditional Use

Use Not Established/Not Recommended: Safety and efficacy are not established for Schizophrenia in children younger than mathbf13 or for Bipolar Mania in children younger than mathbf10. The medicine is also generally not recommended for use in children and adolescents under 18 in some regions.

Conditional Use: Caution is formally required for all elderly patients (,ge 65 years) and those with hepatic impairment, as these groups exhibit documented reduced drug clearance. Caution is further advised in patients with a history of cardiovascular or cerebrovascular disease.

Pregnancy and Lactation: Exposure during the third trimester of pregnancy is associated with a risk of extrapyramidal or withdrawal symptoms in the neonate. The drug is excreted into human milk, requiring careful assessment during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Vesparax (a combination of secobarbital, brallobarbital, and hydroxyzine) based on metabolic enzyme activity, transporter effects, and pharmacodynamic properties of its components.

Clinically Significant Interaction Categories

Category Practical Regulatory Implication
Central Nervous System (CNS) Depressants Co-administration is generally subject to caution and may require dosage reduction of the co-administered agent or continuous monitoring due to potentiated effects on the CNS.
CYP450 Enzyme Modulators Strong inhibitors of CYP3A4 may increase the concentrations of certain Vesparax components. Strong inducers of CYP3A4 may decrease concentrations, potentially leading to loss of clinical effect. Avoidance or dose adjustment is officially recommended.
Medicines that Prolong the QTc Interval Concomitant use with other agents known to prolong the cardiac QTc interval (e.g., certain antiarrhythmics, antipsychotics) is restricted or may be contraindicated due to the risk of additive pharmacodynamic effects.
Alcohol Alcohol significantly enhances the sedative effects of the barbiturate and antihistamine components, necessitating an explicit restriction against its use during treatment.

Other Documented Interactions

The hydroxyzine component is associated with interactions involving P-glycoprotein ( P-gp) inhibitors. The official profile may require monitoring of other P-gp substrate medicines when co-administered with Vesparax, as their plasma concentrations may be increased.

Mechanism of Action

How Vesparax Works

The pharmacological mechanism of Vesparax (Quetiapine) is defined by its selective and complementary actions across major neurotransmitter systems, and involves modulation of activity within key regulatory pathways.

Dual-Target Modulation: D2 and 5-HT2A Receptor Kinetics

This domain covers the primary mechanistic action: the rapid, yet transient, antagonism (blockade) of Dopamine D2 receptors and the high-affinity blockade of Serotonin 5-HT2A receptors in the CNS. The rapid binding and release from D2 receptors prevents sustained blockade of nigrostriatal motor pathways, which results in the modulation of central cognitive and thought pathway signaling while reducing sustained blockade of motor pathway signaling.

Metabolite-Driven Monoamine System Expansion

The mechanism is expanded by the active metabolite, Norquetiapine, which acts as an inhibitor of the Norepinephrine Transporter (NET) and a partial agonist at the Serotonin 5-HT1A receptor. This specialized secondary mechanism enhances the functional availability of both norepinephrine and serotonin, engaging pathways that involve the modulation of norepinephrine and serotonin systems.

High-Affinity Interaction with H1 and alpha1 Receptors

Quetiapine rapidly blocks the Histamine H1 receptors and Adrenergic alpha1 receptors, which are mechanistically distinct from the primary dopamine-serotonin pathways. The intense H1 antagonism rapidly dampens histamine-mediated arousal, producing the physiological consequence of decreased arousal, while alpha1 antagonism affects peripheral vascular tone, resulting in the physiological consequence of reduced peripheral vascular tone, which influences autonomic blood pressure regulation.

Dosage and Administration Information

How to Use Vesparax (Quetiapine)

Administration of Vesparax is strictly by the oral route, utilizing either the immediate-release (IR) tablet or the extended-release (XR) tablet formulations. The two forms follow different dosing schedules. IR tablets are generally taken in divided doses throughout the day, whereas XR tablets are taken once daily, typically in the evening.

Dosing and Frequency Principles

Treatment initiation involves a rapid titration phase over the first few days (typically 3 to 4 days) to reach the necessary maintenance dose. This starting dose can be as low as 25 mg twice daily for certain acute episodes or 50 mg once daily at bedtime for bipolar depression. Maintenance ranges extend up to 750 mg per day for IR tablets and 800 mg per day for XR tablets, depending on the specific use.

Administration Requirements

IR tablets may be taken with or without food. However, XR tablets must be swallowed whole and should not be split, chewed, or crushed; they are typically taken without food or with a light meal. If an XR dose is missed, the standard protocol is to resume administration at the next scheduled time and not to double the dose.

Population-Specific Adjustments

Standard protocols include a lower starting dose and slower titration for specific groups. For example, older adults and individuals with hepatic impairment are typically started on doses such as 25 mg/day or 50 mg/day to account for reduced drug clearance.

Recent Clinical Evidence

Research Evidence / Overview of studies for Vesparax

Evidence for Use in Schizophrenia

Research exploring the use of Vesparax for schizophrenia has utilized short-term randomized controlled trials (RCTs), systematic reviews, and meta-analyses. These studies were applied in research contexts involving fluctuating or unstable symptoms and primarily included adults and adolescents. The research examined outcomes related to overall symptom severity, specific thought disturbances, and changes in agitation. Long-term follow-up research also explored the recurrence of symptoms in participants who met stability criteria, with studies monitoring these outcomes over defined time intervals, including some long-term studies.

However, certain research limitations were noted in the evidence landscape, such as high participant withdrawal rates in some earlier studies. Additionally, there is limited information for long-term outcomes regarding the medication's impact on daily functioning or activity level.


Evidence for Use in Bipolar Disorder

This block will outline the research base for the medicine's evaluation in conditions characterized by mood changes, covering acute manic episodes, acute depressive episodes, and maintenance treatment. Studies examined Vesparax in conditions characterized by fluctuating or episodic manifestations, specifically during phases of heightened symptom activity such as acute manic or mixed episodes, primarily using RCTs over periods of a few weeks.

For bipolar depression, short-term RCTs evaluated the study drug as a monotherapy, measuring changes in depressive symptom severity over intervals typically lasting around eight weeks. Follow-up trials explored the pattern of stability for those who met response criteria during the acute treatment phase.

Long-term studies were conducted to explore outcomes related to systemic or functional imbalance over extended periods, particularly for Bipolar I disorder. Data show patterns related to the measurement of time to recurrence over intervals up to two years, though the results apply only to the populations studied who initially responded well to the treatment.


Evidence for Adjunctive Therapy in Major Depressive Disorder (MDD)

Research explored the use of Vesparax in MDD, applied in studies examining patient-reported experiences for adults who experienced an inadequate response to prior antidepressant treatment. Short-term RCTs that added Vesparax or a placebo to the existing regimen explored short-term symptom changes.

However, the follow-up durations were limited in these studies, meaning there is limited information for long-term outcomes or durability of this adjunctive approach. Furthermore, comparative evidence is lacking for certain groups or is limited when comparing Vesparax against every alternative long-term treatment option.

Key Studies & References

  1. Maintenance therapy with second generation antipsychotics for bipolar disorder - A systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Vesparax (FAQ)

Q: How quickly does Vesparax start working after I take it?

After taking an immediate-release tablet, the active ingredient in Vesparax typically reaches its highest level in the bloodstream in about one to two hours. However, official information indicates that the full therapeutic effects, such as mood stabilization and thought process support, are generally associated with reaching and maintaining the authorized dosage through a gradual adjustment period, often called a titration schedule.

Q: Will I feel sleepy or tired after taking Vesparax?

Regulatory documents list somnolence, which means drowsiness, and fatigue as very common adverse reactions, meaning they may affect 1 in 10 people or more. Official safety information notes that caution is advised regarding activities like driving or operating machinery due to this risk.

Q: What are the most common side effects people report when using Vesparax?

Based on clinical data, the most commonly documented adverse effects include drowsiness, dry mouth, constipation, dizziness, and weight gain. These reactions are classified as Very Common, meaning they are reported in 1 out of every 10 people or more who take the medication.

Q: Is Vesparax a controlled substance?

Vesparax (Quetiapine) is classified by regulatory bodies as a prescription-only drug. It is not currently listed as a federally controlled substance in the United States, but it is available only with a valid prescription.

Q: Why is Vesparax not recommended for pregnant women?

Official prescribing information notes that exposure to the medicine during the third trimester of pregnancy is associated with a risk of extrapyramidal and/or withdrawal symptoms in the newborn after delivery. The decision to use the drug during pregnancy is carefully considered based on whether the potential benefit outweighs the potential risk.

Q: What should I know about Vesparax and breastfeeding?

Official information confirms that the drug is excreted into human milk. Regulatory guidance describes the need for a decision, taking into consideration the importance of the drug to the mother's health and the option to discontinue either the drug or nursing.

Q: Is it okay to drive a car while taking Vesparax?

Official safety warnings indicate that due to the risk of drowsiness, caution is advised regarding engaging in potentially hazardous activities such as driving or operating heavy machinery.

Q: Can Vesparax make me feel better right away?

The achievement of therapeutic effects related to mood stabilization and thought processes is associated with reaching and maintaining the effective dosage. Treatment typically involves a titration phase, which is a gradual adjustment of the dose over the first few days to reach the proper maintenance level.

Q: Does Vesparax impact sleep quality?

The medicine is known to cause drowsiness (somnolence), which is a very common adverse reaction. This is related to the drug's mechanism of action, which involves blocking histamine receptors, contributing to decreased arousal.

Q: Why do doctors prescribe Vesparax?

According to the official indications, Vesparax is prescribed for the treatment of schizophrenia, for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the acute treatment of depressive episodes associated with bipolar disorder.

Q: Is Vesparax an antidepressant or an anxiety drug?

Vesparax is officially classified as an atypical antipsychotic, also known as a second-generation antipsychotic. While it is used in the management of mood disorders, including the depressive episodes associated with bipolar disorder, its pharmacological classification is primarily as an antipsychotic agent.

Q: Can Vesparax cause long-term side effects?

Official safety information notes that certain adverse reactions are specifically associated with long-term exposure to the medicine. These documented risks include the potential development of conditions like Tardive Dyskinesia (involuntary movements) and Cataracts.

Q: Is Vesparax habit-forming or addictive?

The official product label includes a section addressing Drug Abuse and Dependence. The potential for misuse has been discussed in some literature, typically for sedative effects, but the drug is not formally classified under the same controlled substance schedules as highly addictive drugs.

Q: What happens if I forget to take a dose of Vesparax?

Official regulatory guidance describes that if a dose is missed, the instruction is to resume administration at the next scheduled time and not take a double dose to make up for the missed one.

Q: Is it safe to use Vesparax with over-the-counter cold medicine?

Official drug interaction profiles indicate that Vesparax is documented to interact with Central Nervous System (CNS) depressants. Since many over-the-counter cold medicines contain these types of ingredients, co-administration may lead to potentiated (increased) effects on the CNS.

Q: Do natural supplements or vitamins interact with Vesparax?

Yes, official documents specifically list strong CYP3A4 inducers, such as the herbal supplement St. John's wort, as a source of interaction. These interactions can potentially decrease the concentration of Vesparax in the body, which may lead to a loss of the expected clinical effect.

Q: Can teenagers or children use Vesparax?

Official prescribing information confirms that Vesparax is approved for specific pediatric populations. It is indicated for adolescents (13–17 years) for Schizophrenia and for children and adolescents (10–17 years) for Bipolar Mania. Use is not established for children younger than 10 or 13, depending on the condition.

Q: Is Vesparax safe to use if I have kidney problems?

Pharmacokinetic studies indicate that the medicine's clearance is only minimally affected in patients who have severe renal impairment. Official labeling indicates that a starting dose adjustment is generally not required for patients with renal impairment, as studies suggest the medicine's clearance is only minimally affected in those with severe renal impairment.

Q: What is the main benefit or 'claim' supported by the research on Vesparax?

Clinical studies have examined the benefit of the medicine across its authorized uses. Research has focused on outcomes related to improvements in overall symptom severity, specific thought disturbances in schizophrenia, and changes in depressive symptom severity and time to recurrence in bipolar disorder.

Q: Were the clinical trials for Vesparax short-term or long-term?

The research base for Vesparax includes studies of various lengths. Efficacy for acute symptoms was generally demonstrated using short-term randomized controlled trials (RCTs), typically lasting a few weeks. Long-term follow-up research has also been conducted to explore stability and safety outcomes over intervals extending up to two years.

Q: What kind of research has been done on Vesparax?

The evidence supporting the use of Vesparax includes short-term randomized controlled trials (RCTs), systematic reviews, and meta-analyses. This research examined outcomes across the approved patient populations and conditions for which the drug is indicated.

Q: Is it normal to feel a bit dizzy when first starting Vesparax?

Official prescribing information notes that dizziness is a common adverse reaction. It is documented that orthostatic hypotension (a drop in blood pressure when standing) and related dizziness are generally more likely to occur during the initial dose-titration period when treatment is first started.

Q: If I have to stop Vesparax, will I have withdrawal symptoms?

The official safety profile states that abrupt cessation of the medication is associated with documented acute withdrawal symptoms. These symptoms can include nausea, vomiting, and trouble sleeping.

Q: Is Vesparax available as a generic medicine?

The active ingredient in Vesparax, Quetiapine, has been approved by the FDA for generic versions. This means that generic forms of the medicine are widely available.

Q: Does taking Vesparax require regular blood tests?

Official labeling recommends regular monitoring during treatment. This includes performing fasting blood lipid testing at the start of and periodically throughout treatment. Patients with risk factors for diabetes should also have their blood glucose monitored regularly.

Q: Does Vesparax affect blood pressure?

Vesparax is associated with a risk of orthostatic hypotension, which is low blood pressure that occurs when standing up quickly. For children and adolescents, regulatory guidance specifically recommends monitoring blood pressure at the start of and periodically during treatment.

Q: Why is Vesparax sometimes described as a 'newer generation' drug?

Vesparax is formally classified as an atypical antipsychotic. This classification is the preferred term for second-generation antipsychotics, a group of medicines that are newer than the older, 'first-generation' antipsychotics.

Q: Do the effects of Vesparax change over time?

Official safety documents indicate that some effects are tied to the length of exposure. Certain adverse effects, such as dizziness and low blood pressure, are more common during the initial dose-titration period, while others, such as Tardive Dyskinesia, are associated with long-term exposure.

Q: Is Vesparax taken every day or only as needed?

Vesparax is prescribed to be taken in accordance with a daily dosing schedule. The formulation determines the frequency: the extended-release form is typically taken once daily, while the immediate-release form may be taken in divided doses throughout the day.

Q: Is Vesparax a stimulant?

Vesparax is classified as an atypical antipsychotic. A very common adverse reaction listed in regulatory documents is somnolence, or drowsiness, which is the opposite of the effect caused by a stimulant.

Q: What is the recommended duration of treatment with Vesparax?

The duration of treatment is guided by the specific condition and the therapeutic goal. Clinical trials have investigated the medicine's effects in both acute treatment (lasting a few weeks) and maintenance treatment (exploring outcomes over extended periods up to two years).

Q: Are there any specific lifestyle changes recommended when starting Vesparax?

Official safety notes describe explicit cautions, including the avoidance of drinking alcohol due to enhanced sedative effects. They also advise avoiding situations that could lead to becoming overheated or dehydrated while taking the medication.

Q: What happens if I take too much Vesparax?

The full prescribing information contains a section on Overdosage. Reported effects in cases of overdose have included increased somnolence (drowsiness), sedation, a fast heart rate (tachycardia), and low blood pressure (hypotension).

Q: Is Vesparax known to cause changes in weight?

Weight gain is explicitly documented as a very common adverse reaction to the medicine. Official labeling advises that patients should receive regular monitoring of their weight during the course of treatment.

Q: Why is Vesparax sometimes prescribed in combination with other drugs?

Vesparax is officially indicated for use as an adjunctive therapy, meaning it can be added to the regimen of other drugs. For instance, it is indicated to be used in combination with lithium or divalproex for acute manic episodes in Bipolar I Disorder.

How should Vesparax be stored and disposed of?

How to Store and Dispose of Vesparax

Official regulatory guidelines for quetiapine (Vesparax) mandate specific storage and disposal protocols to maintain drug integrity and prevent misuse.

Required Storage Conditions

Requirement Details
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep away from excess moisture, excess heat, and direct light. Do not freeze.
Container Keep the medicine in its original container and ensure the container is tightly closed.
Safety Must be stored out of the sight and reach of children and pets.

Official Disposal Instructions

Do not flush this medicine down the toilet or pour it into a drain. The product is toxic to aquatic life. Unused or expired tablets should be taken to a drug take-back location. If a take-back program is unavailable, mix the tablets with an undesirable substance (like coffee grounds), place the mixture in a sealed bag or container, and discard it in the household trash. Scratch out all personal information on the prescription label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vesparax found in:

A-Z Index: